Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer
NCT02007005
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
37
Enrollment
INDUSTRY
Sponsor class
Conditions
Superficial Bladder Cancer
Interventions
DRUG:
abnobaVISCUM Fraxini
Sponsor
Abnoba Gmbh